摩根大通證券公司：重申Abivax評級

證券之星

2025/01/10

摩根大通證券公司：重申abivax(ABVX.US)評級，由優於大市調整至優於大市評級,目標價由33.00美元調整至33.00美元。Abivax S.A.(ABVX.US)公司簡介：Abivax SA是一家總部位於法國的臨床階段生物技術公司，專注於開發利用人體自然調節機制穩定慢性炎症性疾病患者免疫反應的療法。他們正在3期臨床試驗中評估其候選藥物obefazimod，此藥物用於治療患有中度至重度...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2502896251"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502896251\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2502896251?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-01-10 23:27","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2502896251","market":"us","top_or_hot":-1,"title":"摩根大通證券公司：重申Abivax評級","media":"證券之星","content":"<div>\n<p>摩根大通證券公司：重申abivax(ABVX.US)評級，由優於大市調整至優於大市評級,目標價由33.00美元調整至33.00美元。Abivax S.A.(ABVX.US)公司簡介：Abivax SA是一家總部位於法國的臨床階段生物技術公司，專注於開發利用人體自然調節機制穩定慢性炎症性疾病患者免疫反應的療法。他們正在3期臨床試驗中評估其候選藥物obefazimod，此藥物用於治療患有中度至重度...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110233450a21d1d7c&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>摩根大通證券公司：重申Abivax評級</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n摩根大通證券公司：重申Abivax評級\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">證券之星</strong><span class=\"h-time small\">2025-01-10 23:27</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>摩根大通證券公司：重申abivax(ABVX.US)評級，由優於大市調整至優於大市評級,目標價由33.00美元調整至33.00美元。Abivax S.A.(ABVX.US)公司簡介：Abivax SA是一家總部位於法國的臨床階段生物技術公司，專注於開發利用人體自然調節機制穩定慢性炎症性疾病患者免疫反應的療法。他們正在3期臨床試驗中評估其候選藥物obefazimod，此藥物用於治療患有中度至重度...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110233450a21d1d7c&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110233450a21d1d7c&s=b\">證券之星</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABVX","symbol_name":"Abivax S.A.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110233450a21d1d7c&s=b","article_id":"2502896251","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110233450a21d1d7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2502896251","pubTimestamp":1736522856,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"摩根大通證券公司：重申abivax(ABVX.US)評級，由優於大市調整至優於大市評級,目標價由33.00美元調整至33.00美元。Abivax S.A.(ABVX.US)公司簡介：Abivax SA是一家總部位於法國的臨床階段生物技術公司，專注於開發利用人體自然調節機制穩定慢性炎症性疾病患者免疫反應的療法。他們正在3期臨床試驗中評估其候選藥物obefazimod，此藥物用於治療患有中度至重度活動性潰瘍性結腸炎的成人。其最初重點是炎症性腸病，即涉及胃腸道炎症的慢性疾病，其中兩種最常見的形式是UC和CD。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"ABVX":"Abivax S.A."},"translate_title":"JPMorgan Securities: Reaffirming Abivax Rating","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":0.9},"content_text":"摩根大通證券公司：重申abivax(ABVX.US)評級，由優於大市調整至優於大市評級,目標價由33.00美元調整至33.00美元。Abivax S.A.(ABVX.US)公司簡介：Abivax SA是一家總部位於法國的臨床階段生物技術公司，專注於開發利用人體自然調節機制穩定慢性炎症性疾病患者免疫反應的療法。他們正在3期臨床試驗中評估其候選藥物obefazimod，此藥物用於治療患有中度至重度活動性潰瘍性結腸炎的成人。其最初重點是炎症性腸病，即涉及胃腸道炎症的慢性疾病，其中兩種最常見的形式是UC和CD。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}